These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21161715)

  • 1. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm.
    Wabbels B; Reichel G; Fulford-Smith A; Wright N; Roggenkämper P
    J Neural Transm (Vienna); 2011 Feb; 118(2):233-9. PubMed ID: 21161715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
    Saad J; Gourdeau A
    J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between various clinical outcome assessments in patients with blepharospasm.
    Jankovic J; Kenney C; Grafe S; Goertelmeyer R; Comes G
    Mov Disord; 2009 Feb; 24(3):407-13. PubMed ID: 19053054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.
    Truong DD; Gollomp SM; Jankovic J; LeWitt PA; Marx M; Hanschmann A; Fernandez HH;
    J Neural Transm (Vienna); 2013 Sep; 120(9):1345-53. PubMed ID: 23435927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm.
    Fezza J; Burns J; Woodward J; Truong D; Hedges T; Verma A
    J Neurol Sci; 2016 Aug; 367():56-62. PubMed ID: 27423565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm.
    Jankovic J
    Eur J Neurol; 2009 Dec; 16 Suppl 2():14-8. PubMed ID: 20002742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IncobotulinumtoxinA for the Treatment of Blepharospasm in Toxin-Naïve Subjects: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial.
    Mitsikostas DD; Dekundy A; Sternberg K; Althaus M; Pagan F
    Adv Ther; 2020 Oct; 37(10):4249-4265. PubMed ID: 32779096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects.
    Mitsikostas DD; Dekundy A; Hanschmann A; Althaus M; Scheschonka A; Pagan F; Jankovic J
    Curr Med Res Opin; 2021 Oct; 37(10):1761-1768. PubMed ID: 34384301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
    Jankovic J; Comella C; Hanschmann A; Grafe S
    Mov Disord; 2011 Jul; 26(8):1521-8. PubMed ID: 21520284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. THE EFFECT OF BOTULINUM TOXIN TYPE A IN PATIENTS WITH ESSENTIAL BLEPHAROSPASM.
    Gaćina K; Lešin M; Sarajčev D; Rotim N
    Acta Clin Croat; 2022 Nov; 61(3):379-385. PubMed ID: 37492354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
    Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
    J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported benefit from botulinum toxin treatment for essential blepharospasm: using 2 assessment scales.
    Lee RM; Chowdhury HR; Hyer JN; Smith HB; Jones CA
    Ophthalmic Plast Reconstr Surg; 2013; 29(3):196-7. PubMed ID: 23446304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.
    Roggenkämper P; Jost WH; Bihari K; Comes G; Grafe S;
    J Neural Transm (Vienna); 2006 Mar; 113(3):303-12. PubMed ID: 15959841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combined treatment with orbital and pretarsal botulinum toxin injections in the management of poorly responsive blepharospasm.
    Esposito M; Fasano A; Crisci C; Dubbioso R; Iodice R; Santoro L
    Neurol Sci; 2014 Mar; 35(3):397-400. PubMed ID: 23949734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm.
    Nüssgens Z; Roggenkämper P
    Graefes Arch Clin Exp Ophthalmol; 1997 Apr; 235(4):197-9. PubMed ID: 9143885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
    Pagan FL; Harrison A
    Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
    Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
    Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
    Lolekha P; Choolam A; Kulkantrakorn K
    Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.
    Yoon JS; Kim JC; Lee SY
    Korean J Ophthalmol; 2009 Sep; 23(3):137-41. PubMed ID: 19794937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.